[{"orgOrder":0,"company":"University Hospital Heidelberg","sponsor":"National Center for Tumor Diseases, Heidelberg | Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dacogen","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I","graph3":"University Hospital Heidelberg","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital Heidelberg \/ National Center for Tumor Diseases, Heidelberg | Janssen-Cilag","highestDevelopmentStatusID":"6","companyTruncated":"University Hospital Heidelberg \/ National Center for Tumor Diseases, Heidelberg | Janssen-Cilag"}]
Find Clinical Drug Pipeline Developments & Deals for Dacogen
Details :
Dacogen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Head and Neck Neoplasms.
Reset All
